= Solution
\b[<Learning> and <memory in animals>[memory] provide powerful mechanistic accounts of some psychiatric symptoms, but they are not an adequate single-level definition of all psychiatric disorders.] The most useful claim is that abnormal <learning>, valuation or retrieval can mediate particular symptoms and interact with biological vulnerability and environment. Calling every persistent symptom a “<memory in animals>[memory]” without specifying a computation, mechanism and discriminating prediction would make the account unfalsifiable.
Several causal positions must be separated. A <learning> abnormality could precede illness and increase vulnerability, mediate the expression of an established biological disturbance, or follow from the illness, medication or adverse experiences. A cross-sectional task deficit does not distinguish these possibilities. Nor does a diagnosis identify one latent parameter: poor performance can result from altered <motivation>, perception, <attention>, beliefs or motor output as well as <learning>. <Construct validity> and <external validity> are therefore central, not afterthoughts.
For <schizophrenia>, an influential proposal links <dopamine> dysregulation to <aberrant salience>. Events or internal representations acquire inappropriate significance, and attempts to explain those experiences can contribute to <delusions>. This creates a possible bridge between neurochemistry and acquired belief. It is a theoretical framework rather than evidence that each psychotic belief is an ordinary reinforced association; <psychosis> is also not specific to <schizophrenia>. The account must explain which symptoms it predicts and which remain outside its scope.<Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia by Shitij Kapur>[Abstract and pp. 13–23: proposed salience framework and its stated explanatory scope]{ref}
A pharmacological experiment provides a more direct test of one link. Healthy volunteers performed causal associative <learning> during randomized <ketamine> and placebo sessions with <functional magnetic resonance imaging>. The drug perturbed right-frontal responses related to violated expectations, and individual neural responses were related to subsequently assessed perceptual and belief-like drug effects. This supports an association between altered learning-related processing and psychotomimetic experience. It does not show that <ketamine> reproduces the developmental course of <schizophrenia>, or that the observed imaging signal is the unique mediator of a <delusion>. <Pharmacology> causally changes the drug condition; the relationship between an imaging response and a symptom remains a separate inferential step.<Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis by Philip R. Corlett and others>[Abstract; Results and Comment, pp. 611–621: randomized drug challenge, learning responses and symptom relations]{ref}
Prospective evidence helps with temporal ordering. Elevated striatal <dopamine> synthesis capacity was observed before transition to psychotic disorder in a high-risk cohort. That finding is important biological evidence, but a PET synthesis-capacity estimate does not directly measure trial-wise <reward prediction errors>, and elevated capacity does not establish a specific <learning> algorithm. It also does not imply that every high-risk person or every diagnosed patient has the same abnormality. A <learning> account should connect this biological vulnerability to task-defined computations rather than substitute one measure for another.<Dopamine synthesis capacity before onset of psychosis by Oliver D. Howes and others>[Abstract and pp. 1311–1317: prospective imaging and transition-group comparison]{ref}
For <major depressive disorder>, low expectations of control, persistent negative interpretations and reduced engagement with rewarding opportunities are plausible learning-related mechanisms. <Learned helplessness> provides a specific model of how uncontrollability can change later behaviour; <attributional style> helps explain generalization and persistence in human accounts. These mechanisms are neither a moral judgment about the individual nor proof that all adverse circumstances are controllable. Sleep, bodily symptoms, neurodevelopmental factors and the diversity of depressive presentations remain part of the explanandum.
Behavioural evidence is more precise than a global claim that depressed people “cannot learn.” In a probabilistic reward task, unmedicated depressed participants showed reduced development of response bias toward a more frequently rewarded stimulus, with analyses implicating integration of reinforcement history rather than total absence of response to an individual reward. This separates one aspect of <reward learning> from subjective pleasure and from every component of <anhedonia>. The direction of causation remains open in a cross-sectional comparison.<Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task by Diego A. Pizzagalli and others>[Abstract and trial-history analyses: asymmetric reinforcement and response bias]{ref}
Treatment findings can also link biological and cognitive levels. An acute norepinephrine-reuptake manipulation changed emotional processing in depressed participants before subjective mood changed. That observation is consistent with pharmacologically altered experience processing contributing to later improvement; it does not prove that the early task change mediates every later clinical response. <Learning> and <pharmacology> can interact rather than constitute mutually exclusive treatments. A drug might alter the conditions under which corrective experiences are encoded, while behavioural <intervention> supplies those experiences.<Effect of acute antidepressant administration on negative affective bias in depressed patients by Catherine J. Harmer and others>[Abstract; Methods and Results: early emotional-processing effects without immediate mood change]{ref}
The <learning> perspective generates concrete treatment hypotheses. In threat disorders, <extinction learning> suggests improving safety <learning> and its retrieval across contexts, rather than merely suppressing an immediate response. A randomized pilot study combined <D-cycloserine> or placebo with virtual-reality exposure to heights in people with acrophobia. Greater improvement in the adjunct condition provided an early proof of concept for facilitating a specified <learning> experience. The small, specific trial does not establish a general cognitive enhancer for all diagnoses, and an <intervention> that facilitates <learning> need not selectively strengthen desirable information. Treatment timing and the quality of the <learning> episode are therefore empirical issues.<Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear by Kerry J. Ressler and others>[Abstract and pp. 1136–1144: blinded randomized pilot, virtual glass-elevator exposure and follow-up]{ref}
For psychotic symptoms, a <learning> account predicts that reducing inappropriate salience may permit new interpretation without instantly deleting established beliefs. For depression, it motivates tests of changes in reward sensitivity, information integration and expectations, with functional recovery as an outcome. These are treatment-development hypotheses, not conclusions that a single task parameter should dictate care. Symptom improvement, correction of a proposed mechanism and prevention of relapse require separate measurements; changing a laboratory score is not sufficient evidence of benefit.
The broad claim becomes convincing only when models predict specific patterns, survive controls for performance confounds, and show temporally appropriate changes linked to symptoms. Comparisons with unaffected high-risk individuals, longitudinal designs and mechanism-sensitive randomized trials can distinguish vulnerability, mediation and consequence. <Learning> and <memory in animals>[memory] are therefore valuable explanatory levels and possible treatment targets, especially for particular acquired responses and beliefs. They do not replace the biological, developmental and social causes of psychiatric illness, and they should not turn diagnostic heterogeneity into one assumed defect.
Back to article page
